» Articles » PMID: 21491187

Computer-assisted Design for Paracetamol Masking Bitter Taste Prodrugs

Overview
Journal J Mol Model
Publisher Springer
Specialty Molecular Biology
Date 2011 Apr 15
PMID 21491187
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

It is believed that the bitter taste of paracetamol, a pain killer drug, is due to its hydroxyl group. Hence, it is expected that blocking the hydroxy group with a suitable linker could inhibit the interaction of paracetamol with its bitter taste receptor/s and hence masking its bitterness. Using DFT theoretical calculations we calculated proton transfers in ten different Kirby's enzyme models, 1-10. The calculation results revealed that the reaction rate is linearly correlated with the distance between the two reactive centers (r(GM)) and the angle of the hydrogen bonding (α) formed along the reaction pathway. Based on these results three novel tasteless paracetamol prodrugs were designed and the thermodynamic and kinetic parameters for their proton transfers were calculated. Based on the experimental t(1/2) (the time needed for the conversion of 50% of the reactants to products) and EM (effective molarity) values for processes 1-10 we have calculated the t(1/2) values for the conversion of the three prodrugs to the parental drug, paracetamol. The calculated t(1/2) values for ProD 1-3 were found to be 21.3 hours, 4.7 hours and 8 minutes, respectively. Thus, the rate by which the paracetamol prodrug undergoes cleavage to release paracetamol can be determined according to the nature of the linker of the prodrug (Kirby's enzyme model 1-10). Further, blocking the phenolic hydroxyl group by a linker moiety is believed to hinder the paracetamol bitterness.

Citing Articles

Process Modelling, Scale-Up and Characterization of Acetaminophen Spray Dried Milk Powder as Novel Pediatric Dosage Form.

Shah H, Syamala U, Chaudhari K, Savjani J, Butani S Pharm Res. 2022; 39(11):2885-2903.

PMID: 35931906 DOI: 10.1007/s11095-022-03354-3.


Enzyme Models-From Catalysis to Prodrugs.

Breijyeh Z, Karaman R Molecules. 2021; 26(11).

PMID: 34071328 PMC: 8198240. DOI: 10.3390/molecules26113248.


Design, synthesis, and in vitro kinetics study of atenolol prodrugs for the use in aqueous formulations.

Karaman R, Qtait A, Dajani K, Abu Lafi S ScientificWorldJournal. 2014; 2014:248651.

PMID: 24526887 PMC: 3913492. DOI: 10.1155/2014/248651.


Design, synthesis and in vitro kinetic study of tranexamic acid prodrugs for the treatment of bleeding conditions.

Karaman R, Ghareeb H, Dajani K, Scrano L, Hallak H, Abu-Lafi S J Comput Aided Mol Des. 2013; 27(7):615-35.

PMID: 23881217 DOI: 10.1007/s10822-013-9666-2.


Computationally designed prodrugs of statins based on Kirby's enzyme model.

Karaman R, Amly W, Scrano L, Mecca G, Bufo S J Mol Model. 2013; 19(9):3969-82.

PMID: 23835602 DOI: 10.1007/s00894-013-1929-2.


References
1.
Karaman R, Pascal R . A computational analysis of intramolecularity in proton transfer reactions. Org Biomol Chem. 2010; 8(22):5174-8. DOI: 10.1039/c0ob00252f. View

2.
Karaman R, Hallak H . Computer-assisted design of pro-drugs for antimalarial atovaquone. Chem Biol Drug Des. 2010; 76(4):350-60. DOI: 10.1111/j.1747-0285.2010.01018.x. View

3.
Karaman R . Prodrugs of aza nucleosides based on proton transfer reaction. J Comput Aided Mol Des. 2010; 24(12):961-70. DOI: 10.1007/s10822-010-9389-6. View

4.
Bruice T, Pandit U . INTRAMOLECULAR MODELS DEPICTING THE KINETIC IMPORTANCE OF "FIT" IN ENZYMATIC CATALYSIS. Proc Natl Acad Sci U S A. 1960; 46(4):402-4. PMC: 222851. DOI: 10.1073/pnas.46.4.402. View

5.
Karaman R . The effective molarity (EM)--a computational approach. Bioorg Chem. 2010; 38(4):165-72. DOI: 10.1016/j.bioorg.2010.04.002. View